5 reasons Pharma still favors SAS software for clinical in 2010
Posted by Keith ward on Mon, Jan 18, 2010 @ 10:07 AM
In 1897, after reading his obituary in the New York Journal, author and humorist Mark Twain famously quipped, “The reports of my death are greatly exaggerated.” Similarly, for life sciences organizations, the clinical-trials stalwart that are SAS solutions, remain as viable, relevant, industry-leading, and cost-effective as ever.
The economic forecast for 2010 continues to look challenging to say the least; global competition grows more intense; the regulatory compliance climate index only moves in one direction: more complex; and the case for collaborating on research endeavors grows more compelling every day; all the more reason to rely on SAS, the only end-to-end solution that can drive efficiencies throughout a drug’s lifecycle.
SAS enables businesses, big, small, and in-between to leverage enterprise-scale solutions to develop, execute, and manage the collection, sharing, transformation, analysis, and submission of clinical research data, while driving down costs and ratcheting up time-to-market and profitability.
Is SAS still the hands-down leader in managing clinical trial data? Consider these facts:
• The FDA and most global regulatory bodies review clinical data summaries for NDA, eCTD, and NeeS submissions using SAS analytics
• Taking data out of SAS and putting it back into SAS datasets creates unwarranted and unpredictable liabilities
• SAS’s proven track record is decades long
• SAS has a deep bench of experienced professionals ensuring faster programming and quicker time to market
• When it comes to clinical trials analysis, SAS is the de facto industry standard
Contact DZS Today!
